# A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

> **NCT01631279** · PHASE1,PHASE2 · TERMINATED · sponsor: **Proacta, Incorporated** · enrollment: 33 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** PR610

## Key facts

- **NCT ID:** NCT01631279
- **Lead sponsor:** Proacta, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2015-03
- **Final completion:** 2015-08
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Study was prematurely discontinued due to unacceptable toxicity.
- **Last updated:** 2014-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01631279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01631279, "A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01631279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*